Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and markets pain management medications. The company is headquartered in Stoughton, Massachusetts.
| Revenue (TTM) | $796.33M |
| Gross Profit (TTM) | $710.08M |
| EBITDA | $425.05M |
| Operating Margin | 16.00% |
| Return on Equity | 27.40% |
| Return on Assets | 7.60% |
| Revenue/Share (TTM) | $25.06 |
| Book Value | $9.64 |
| Price-to-Book | 3.84 |
| Price-to-Sales (TTM) | 1.47 |
| EV/Revenue | 1.993 |
| EV/EBITDA | 3.86 |
| Quarterly Earnings Growth (YoY) | -46.60% |
| Quarterly Revenue Growth (YoY) | 8.90% |
| Shares Outstanding | $32.43M |
| Float | $32.05M |
| % Insiders | 1.16% |
| % Institutions | 127.83% |
Volatility is currently expanding
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
COLL, IRWD, AMTB and DUK stand out as defensive stock picks as investors rotate from AI-driven tech amid the ongoing sell-off and seek safer sectors.
BBCP, KUBTY, ADM, COLL and W have been added to the Zacks Rank #1 (Strong Buy) List on July 6, 2026.
COLL gains momentum as strong Jornay PM growth and the Azstarys acquisition boosted 2026 guidance, strengthening its ADHD franchise and revenue outlook.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
STOUGHTON, Mass., June 05, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced it awarded inducement grants on June 1, 2026 under the Company's 2026 Inducement Plan (the 2026 Inducement Plan).
STOUGHTON, Mass., May 27, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that its management will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference.
– Adds Highly Complementary and Differentiated Medicine with Significant Growth Potential to Collegium's Existing ADHD Portfolio –
Collegium Pharmaceutical, Inc. (COLL) Q1 2026 Earnings Call Transcript
– Generated Quarterly Net Revenues of $193.5 Million, Up 9% Year-over-Year – – Generated JORNAY PM ® Quarterly Net Revenue of $38.9 Million, Up 36% Year-over-Year – – On Track to Close Acquisition of AZSTARYS ® in Second Quarter of 2026, Adding Highly Complementary and Differentiated Medicine with Significant Growth Potential to Collegium's Existing ADHD Portfolio – – Generated Quarterly Pain Portfolio Net Revenues of $154.6 Million, Up 4% Year-over-Year – – Ended Q1'26 with Cash, Cash Equivalents and Marketable Securities of $421.8 Million – – Reaffirmed Full-Year 2026 Guidance for the Current Business – – Conference Call Scheduled for Today at 8:00 a.m. ET – STOUGHTON, Mass.
